Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Innoviva, Inc. (INVA : NSDQ)
 
 • Company Description   
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.

Number of Employees: 127

 
 • Price / Volume Information   
Yesterday's Closing Price: $18.61 Daily Weekly Monthly
20 Day Moving Average: 575,618 shares
Shares Outstanding: 62.68 (millions)
Market Capitalization: $1,166.39 (millions)
Beta: 0.35
52 Week High: $21.28
52 Week Low: $15.20
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 3.50% -4.26%
12 Week 2.93% 7.69%
Year To Date 7.26% 7.95%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1350 OLD BAYSHORE HIGHWAY SUITE 400
-
BURLINGAME,CA 94010
USA		 ph: 650-238-9600
fax: 650-827-8690		 innoviva@argotpartners.com http://www.inva.com
 
 • General Corporate Information   
Officers
Pavel Raifeld - Chief Executive Officer
Mark DiPaolo, Esq. - Chairman
Stephen Basso - Chief Financial Officer
Odysseas Kostas - Director
Jules Haimovitz - Director

Peer Information
Innoviva, Inc. (AGN.)
Innoviva, Inc. (NVS)
Innoviva, Inc. (NVO)
Innoviva, Inc. (LLY)
Innoviva, Inc. (RHHBY)
Innoviva, Inc. (JNJ)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: Large Cap Pharma
Sector: Medical
CUSIP: 45781M101
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
Share - Related Items
Shares Outstanding: 62.68
Most Recent Split Date: (:1)
Beta: 0.35
Market Capitalization: $1,166.39 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/30/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: 12.24
PEG Ratio: -
Price Ratios
Price/Book: 1.80
Price/Cash Flow: 5.43
Price / Sales: 3.15
EPS Growth
vs. Year Ago Period: -45.65%
vs. Previous Quarter: -56.14%
Sales Growth
vs. Year Ago Period: 14.37%
vs. Previous Quarter: -3.46%
ROE
03/31/25 - 15.77
12/31/24 - 18.50
09/30/24 - 20.84
ROA
03/31/25 - 8.41
12/31/24 - 10.05
09/30/24 - 11.38
Current Ratio
03/31/25 - 2.48
12/31/24 - 2.35
09/30/24 - 1.79
Quick Ratio
03/31/25 - 2.30
12/31/24 - 2.21
09/30/24 - 1.64
Operating Margin
03/31/25 - 28.49
12/31/24 - 35.18
09/30/24 - 40.06
Net Margin
03/31/25 - -16.15
12/31/24 - 6.52
09/30/24 - 18.31
Pre-Tax Margin
03/31/25 - -12.53
12/31/24 - 10.42
09/30/24 - 20.95
Book Value
03/31/25 - 10.32
12/31/24 - 11.03
09/30/24 - 10.68
Inventory Turnover
03/31/25 - 0.94
12/31/24 - 1.03
09/30/24 - 1.14
Debt-to-Equity
03/31/25 - 0.40
12/31/24 - 0.37
09/30/24 - 0.38
Debt-to-Capital
03/31/25 - 28.41
12/31/24 - 27.05
09/30/24 - 27.69
 

Powered by Zacks Investment Research ©